Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
CytoSorbents 2017 - Propelling the Company to the "Next Level"
-
Cytosorbents (CTSO) Prices 2.22M Share Follow-On Offering at $4.50
-
CytoSorbents Announces Pricing of Follow-On Offering
-
Maxim Group Reiterates Buy Rating and $10 PT on Cytosorbents (CTSO) Following Dr. Carl June's Election to the Advisory Board
-
Maxim Maintains Buy Rating and $10 PT on Cytosorbents (CTSO) Following Positive CytoSorb Cases to Treat HLH & CRS Relavance in Cancer Immunotherapy
-
Maxim Group Reiterates Buy Rating and $110 PT on Cytosorbents (CTSO) Following Dr. Reddy Partnership
-
CytoSorbents to Present at the Maxim Group - Haitong Securities Inaugural Healthcare Investor and Partnering Conference
-
CytoSorbents (CTSO) PT Raised to $10 at Maxim Group
-
CytoSorbents (CSTO) Bullish View Reiterated at Maxim Group on Commercial Launch of CytoSorb for Cardiac Surgery
-
CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb® Sales
-
CytoSorbents (CTSO) Bullish View Reiterated at Maxim Group as Two Distributors Added
-
Cytosorbents (CTSO): Secures $10M Non-Dilutive Financing - Maxim
-
Maxim Group Starts CytoSorbents (CTSO) at Buy

